Novo Nordisk begins building $130 million lab facility in Denmark

31 October 2014

Danish insulin giant Novo Nordisk (NOVN: N) has made a 750 million Danish kroner ($130 million) investment in new laboratories at the company’s research and development campus. Situated in Malov in Denmark, the lab is expected to be ready for occupation in early 2016.

The Diabetes Research House will accommodate around 350 employees, and in the construction phase is expected to generate more than 1,000 jobs from outside the company.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry. Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK